Olivier S Descamps

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2139381/publications.pdf

Version: 2024-02-01

27 papers 8,407 citations

448610 19 h-index 28 g-index

28 all docs

28 docs citations

times ranked

28

9241 citing authors

#	Article	IF	CITATIONS
1	Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis, 2021, 319, 108-117.	0.4	18
2	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	1.6	39
3	Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy. Acta Cardiologica, 2021, 76, 227-235.	0.3	3
4	Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis, 2020, 292, 178-187.	0.4	41
5	Evolving concepts on the management of dyslipidaemia. Acta Clinica Belgica, 2020, 75, 80-90.	0.5	3
6	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.4	137
7	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Supplements, 2019, 39, e1-e8.	1.2	31
8	Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II _{CHD}). Acta Clinica Belgica, 2019, 74, 399-404.	0.5	4
9	A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial) Tj ETQq1 1 0.784314 rgBT /	/Ov e ckock	10 5 f 50 417 T
10	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	1.5	189
11			
11	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	1.2	216
12	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979.	0.8	216
	Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for		
12	Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979. Systematic review of published Phase 3 data on antiâ€PCSK9 monoclonal antibodies in patients with	0.8	11
12 13	Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979. Systematic review of published Phase 3 data on antiâ€PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. British Journal of Clinical Pharmacology, 2016, 82, 1412-1443. Variability of the LDL-C lowering response to ezetimibe and ezetimibeÂ+Âstatin therapy in	0.8	11 36
12 13 14	Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979. Systematic review of published Phase 3 data on antiâ€PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. British Journal of Clinical Pharmacology, 2016, 82, 1412-1443. Variability of the LDL-C lowering response to ezetimibe and ezetimibeÂ+Âstatin therapy in hypercholesterolemic patients. Atherosclerosis, 2015, 240, 482-489. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing	0.8	11 36 29
12 13 14	Cardiology, 2018, 72, 96-118. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. International Journal of Clinical Practice, 2017, 71, e12979. Systematic review of published Phase 3 data on antiâ€PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. British Journal of Clinical Pharmacology, 2016, 82, 1412-1443. Variability of the LDL-C lowering response to ezetimibe and ezetimibeÂ+Âstatin therapy in hypercholesterolaemic patients. Atherosclerosis, 2015, 240, 482-489. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	0.8 1.1 0.4	11 36 29

#	Article	IF	CITATIONS
19	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis, 2014, 233, 83-90.	0.4	52
20	Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet, The, 2013, 381, 1293-1301.	6.3	485
21	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
22	Plant sterols and cardiovascular disease: a systematic review and meta-analysisâ€. European Heart Journal, 2012, 33, 444-451.	1.0	180
23	A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis, 2012, 222, 564-566.	0.4	9
24	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
25	Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. Atherosclerosis, 2011, 217, 308-321.	0.4	43
26	Lipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children. Journal of Lipid Research, 2005, 46, 2405-2414.	2.0	34
27	Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis, 2004, 172, 287-298.	0.4	36